A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.

deep-learning digital pathology immunohistochemistry protein-based subtypes targeted therapy upper tract urothelial carcinoma whole slide images

Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
Mar 2024
Historique:
revised: 08 02 2024
received: 24 11 2023
accepted: 26 02 2024
medline: 20 3 2024
pubmed: 20 3 2024
entrez: 20 3 2024
Statut: ppublish

Résumé

Upper tract urothelial carcinoma (UTUC) is a rare and aggressive, yet understudied, urothelial carcinoma (UC). The more frequent UC of the bladder comprises several molecular subtypes, associated with different targeted therapies and overlapping with protein-based subtypes. However, if and how these findings extend to UTUC remains unclear. Artificial intelligence-based approaches could help elucidate UTUC's biology and extend access to targeted treatments to a wider patient audience. Here, UTUC protein-based subtypes were identified, and a deep-learning (DL) workflow was developed to predict them directly from routine histopathological H&E slides. Protein-based subtypes in a retrospective cohort of 163 invasive tumors were assigned by hierarchical clustering of the immunohistochemical expression of three luminal (FOXA1, GATA3, and CK20) and three basal (CD44, CK5, and CK14) markers. Cluster analysis identified distinctive luminal (N = 80) and basal (N = 42) subtypes. The luminal subtype mostly included pushing, papillary tumors, whereas the basal subtype diffusely infiltrating, non-papillary tumors. DL model building relied on a transfer-learning approach by fine-tuning a pre-trained ResNet50. Classification performance was measured via three-fold repeated cross-validation. A mean area under the receiver operating characteristic curve of 0.83 (95% CI: 0.67-0.99), 0.8 (95% CI: 0.62-0.99), and 0.81 (95% CI: 0.65-0.96) was reached in the three repetitions. High-confidence DL-based predicted subtypes showed significant associations (p < 0.001) with morphological features, i.e. tumor type, histological subtypes, and infiltration type. Furthermore, a significant association was found with programmed cell death ligand 1 (PD-L1) combined positive score (p < 0.001) and FGFR3 mutational status (p = 0.002), with high-confidence basal predictions containing a higher proportion of PD-L1 positive samples and high-confidence luminal predictions a higher proportion of FGFR3-mutated samples. Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes. Taken together, our DL workflow can predict protein-based UTUC subtypes, associated with the presence of targetable alterations, directly from H&E slides.

Identifiants

pubmed: 38504364
doi: 10.1002/2056-4538.12369
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12369

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : TRR305 (projectsZ01andZ02)
Organisme : Deutsche Forschungsgemeinschaft
ID : TRR374 (projectINF)
Organisme : Deutsche Forschungsgemeinschaft
ID : 493665037
Organisme : Interdisziplinäre Zentrum für Klinische Forschung FAU Erlangen-Nürnberg
Organisme : Else Kröner-Fresenius-Stiftung
ID : 2020_EKEA.129
Organisme : Bayerisches Zentrum für Krebsforschung
Organisme : Bundesministerium für Bildung und Forschung
ID : 01KD2211B
Organisme : KWF Kankerbestrijding

Informations de copyright

© 2024 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

Références

WHO Classification of Tumours Editorial Board. Tumours of the urinary tract. In: Urinary and Male Genital Tumours (5th edn), Compérat E, Netto G, Tsuzuki T (Eds). Lyon: International Agency for Research on Cancer, 2022; 131-191.
Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 2023; 84: 49-64.
De Lorenzis E, Albo G, Longo F, et al. Current knowledge on genomic profiling of upper tract urothelial carcinoma. Genes (Basel) 2021; 12: 333.
Hassler MR, Bray F, Catto JWF, et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur Urol 2020; 78: 209-220.
Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013; 189: 1214-1221.
Zhao L, Lee VHF, Ng MK, et al. Molecular subtyping of cancer: current status and moving toward clinical applications. Brief Bioinform 2019; 20: 572-584.
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25: 152-165.
Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014; 111: 3110-3115.
Marzouka N-A-D, Eriksson P, Rovira C, et al. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 2018; 8: 3737.
Mo Q, Nikolos F, Chen F, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst 2018; 110: 448-459.
Rebouissou S, Bernard-Pierrot I, de Reyniès A, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014; 6: 244ra291.
Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017; 171: 540-556.
Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020; 77: 420-433.
Kujtan L, Hussain A, Subramanian J, et al. The evolving genomic landscape in urothelial cancer. Curr Opin Oncol 2018; 30: 197-202.
Fujii Y, Sato Y, Suzuki H, et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 2021; 39: 793-809.e8.
Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 2017; 72: 641-649.
Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 2019; 10: 2977.
Weyerer V, Stoehr R, Bertz S, et al. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol 2021; 39: 4011-4019.
Woerl AC, Eckstein M, Geiger J, et al. Deep learning predicts molecular subtype of muscle-invasive bladder cancer from conventional histopathological slides. Eur Urol 2020; 78: 256-264.
Bhinder B, Gilvary C, Madhukar NS, et al. Artificial intelligence in cancer research and precision medicine. Cancer Discov 2021; 11: 900-915.
Bontoux C, Rialland T, Cussenot O, et al. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases. Virchows Arch 2021; 478: 637-645.
Dadhania V, Zhang M, Zhang L, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016; 12: 105-117.
Jung M, Kim B, Moon KC. Immunohistochemistry of cytokeratin (CK) 5/6, CD 44 and CK 20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma. Histopathology 2019; 74: 483-493.
Sikic D, Keck B, Wach S, et al. Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS One 2017; 12: e0179602.
van Doeveren T, van Leeuwen PJ, Aben KKH, et al. Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: the REBACARE-trial. Contemp Clin Trials Commun 2018; 9: 121-129.
Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016; 70: 106-119.
Guo CC, Czerniak B. Bladder cancer in the genomic era. Arch Pathol Lab Med 2019; 143: 695-704.
Czerniak B, Dinney C, McConkey D. Origins of bladder cancer. Annu Rev Pathol 2016; 11: 149-174.
McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
Eckstein M, Erben P, Kriegmair MC, et al. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer 2019; 106: 234-243.
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015-1026.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-1920.
Pfannstiel C, Strissel PL, Chiappinelli KB, et al. The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol Res 2019; 7: 923-938.
van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 7743-7748.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, 2020. Available from: https://www.R-project.org/.
Bankhead P, Loughrey MB, Fernández JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017; 7: 16878.
He K, Zhang X, Ren S, et al. Deep residual learning for image recognition. In 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2016; 770-778. https://doi.org/10.1109/CVPR.2016.90.
Russakovsky O, Deng J, Su H, et al. ImageNet large scale visual recognition challenge. Int J Comput Vis 2015; 115: 211-252.
Taber A, Christensen E, Lamy P, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun 2020; 11: 4858.
Nogueira LM, Yip W, Assel MJ, et al. Survival impact of variant histology diagnosis in upper tract urothelial carcinoma. J Urol 2022; 208: 813-820.
Ward JH Jr. Hierarchical grouping to optimize an objective function. J Am Stat Assoc 1963; 58: 236-244.
Murtagh F, Legendre P. Ward's hierarchical agglomerative clustering method: which algorithms implement Ward's criterion? J Classif 2014; 31: 274-295.
Macenko M, Niethammer M, Marron JS, et al. A method for normalizing histology slides for quantitative analysis. In 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro (IEEE), 2009; 1107-1110. https://doi.org/10.1109/ISBI.2009.5193250.
Laleh NG, Muti HS, Loeffler CML, et al. Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Med Image Anal 2022; 79: 102474.
Lu MY, Williamson DFK, Chen TY, et al. Data-efficient and weakly supervised computational pathology on whole-slide images. Nat Biomed Eng 2021; 5: 555-570.
Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med 2018; 24: 1559-1567.
Schrammen PL, Ghaffari Laleh N, Echle A, et al. Weakly supervised annotation-free cancer detection and prediction of genotype in routine histopathology. J Pathol 2022; 256: 50-60.
Russell SJ, Norvig P. Artificial Intelligence: A Modern Approach (3rd edn). Pearson: London, 2010.
Howard J, Gugger S. Fastai: a layered API for deep learning. Information 2020; 11: 108.
Paszke A, Gross S, Massa F, et al. Pytorch: an imperative style, high-performance deep learning library. In Advances in Neural Information Processing Systems 32 (NeurIPS 2019), 2019. https://doi.org/10.48550/arXiv.1912.01703.
Smith LN, Topin N. Super-convergence: very fast training of neural networks using large learning rates. In Artificial Intelligence and Machine Learning for Multi-Domain Operations Application. Proceedings of SPIE, 2019; 369-386. https://doi.org/10.1117/12.2520589.

Auteurs

Miriam Angeloni (M)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Thomas van Doeveren (T)

Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands.

Sebastian Lindner (S)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Patrick Volland (P)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Jorina Schmelmer (J)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Sebastian Foersch (S)

Institute of Pathology, University Medical Center Mainz, Mainz, Germany.

Christian Matek (C)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Robert Stoehr (R)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Carol I Geppert (CI)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Hendrik Heers (H)

Department of Urology, Philipps-Universität Marburg, Marburg, Germany.

Sven Wach (S)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Helge Taubert (H)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Danijel Sikic (D)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Bernd Wullich (B)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Geert Jlh van Leenders (GJ)

Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands.

Vasily Zaburdaev (V)

Department of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany.

Markus Eckstein (M)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.

Joost L Boormans (JL)

Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands.

Fulvia Ferrazzi (F)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Nephropathology, Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Veronika Bahlinger (V)

Institute of Pathology, University Hospital Erlangen-Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.

Classifications MeSH